1 / 12

Clinical results of Hyperopic Wavefront LASIK with the Bausch & Lomb Zyoptix platform

Clinical results of Hyperopic Wavefront LASIK with the Bausch & Lomb Zyoptix platform. Dr Haralabos Eleftheriadis, M.D Ultralase Clinic Bristol UK. Financial Interest: Travelling Grants received from Bausch & Lomb. Purpose.

rafal
Download Presentation

Clinical results of Hyperopic Wavefront LASIK with the Bausch & Lomb Zyoptix platform

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical results of Hyperopic Wavefront LASIK with the Bausch & Lomb Zyoptix platform Dr Haralabos Eleftheriadis, M.D Ultralase Clinic Bristol UK Financial Interest: Travelling Grants received from Bausch & Lomb ASCRS Symposium 2009, San Francisco, April 3-8,

  2. Purpose To study the visual and refractive results of hyperopia and compound hyperopic astigmatism treated with LASIK using the wavefront Bausch & Lomb (B&L) Zyoptix platform and flaps created with the femtosecond IntraLase laser ASCRS Symposium 2009, San Francisco, April 3-8,

  3. Methods 1 • Hyperopic patients undergoing wavefront LASIK with the B&L Zyoptix platform were studied prospectively • Flaps were created with the femtosecond IntraLase laser • Data were collected at months 1, 2, 3, 6 and at the time of discharge ASCRS Symposium 2009, San Francisco, April 3-8,

  4. Methods 2 • Studied parameters were uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), manifest refraction as well as safety, efficacy and predictability • Only eyes with preoperative manifest spherical equivalent (MSE) of ≤+4.00 dioptres (D), BCVA of ≥20/20 and target refraction of emmetropia were included in this study • Results at the time of discharge are presented below as mean ± standard deviation and range ASCRS Symposium 2009, San Francisco, April 3-8,

  5. Results 1 • 114 eyes (56 right eyes) • 59 patients (33 male) • Age 52±7 years (range 38 to 65) • Preoperative MSE +2.11±0.82 D (range +0.75 to +4.00) • Preoperative Sphere: +2.47±0.87 D (range +1.00 to +4.25 D) • Preoperative Cylinder: -0.70±0.40 D (range -0.25 to -2.50 D) • Time of discharge: 8.3±3 months (range 3 to 22) ASCRS Symposium 2009, San Francisco, April 3-8,

  6. Results 2 Efficacy Index at Discharge 95.8% ASCRS Symposium 2009, San Francisco, April 3-8,

  7. Results 3 Safety index at Discharge 98% ASCRS Symposium 2009, San Francisco, April 3-8,

  8. Results 4 ±0.50 D: 88% ±1.00 D: 99% ASCRS Symposium 2009, San Francisco, April 3-8,

  9. Results 5 ≤0.5 D: 84% ≤1.00D: 98% ASCRS Symposium 2009, San Francisco, April 3-8,

  10. Results 6 Attempted vs Achieved SE at Discharge OVERCORRECTED Y=-0.110+1.093*X, R2=0.88 UNDERCORRECTED ASCRS Symposium 2009, San Francisco, April 3-8,

  11. Results 7 Evolution of Spherical Equivalent 5 4 3 2 SphericalEquivalent 1 0 -1 Preop Discharge 6 Months 12 Months 2 Months 3 Months 9 Months 1 Month 3 eyes (2.6%) required enhancement procedures ASCRS Symposium 2009, San Francisco, April 3-8,

  12. Conclusions • Wavefront guided LASIK for hyperopia and compound hyperopic astigmatism with the Zyoptix Bausch & Lomb platform and flaps created with the IntraLase femtosecond laser is • Highly effective • Very safe refractive procedure • It yields very accurate visual and refractive results ASCRS Symposium 2009, San Francisco, April 3-8,

More Related